Subgroup analysis comparing median PFS and OS among patients with different characteristics
| Variables | PFS | OS | ||
|---|---|---|---|---|
| Median PFS (months, 95% CI) | P | Median OS (months, 95% CI) | P | |
| Age, years | ||||
| < 55 | 4.4 (3.0–5.8) | 0.159 | 24.7 (10.3–39.0) | 0.408 |
| ≥ 55 | 6.2 (2.5–9.9) | 15.6 (10.0–21.3) | ||
| ECOG performance status | ||||
| 0 | 6.1 (4.1–8.0) | 0.022 | 22.0 (14.0–30.0) | 0.242 |
| 1 | 3.6 (1.6–5.7) | 9.1 (1.9–16.2) | ||
| Hormone receptor status | ||||
| Positive | 4.4 (2.0–6.8) | 0.194 | 18.2 (0.0–37.9) | 0.744 |
| Negative | 6.0 (4.1–7.8) | 15.8 (11.9–19.7) | ||
| Visceral metastasis | ||||
| No | 4.8 (2.7–7.0) | 0.579 | 22.0 (9.6–34.3) | 0.884 |
| Yes | 5.2 (3.2–7.2) | 17.4 (10.0–24.8) | ||
| Chest wall recurrence | ||||
| No | 5.2 (3.2–7.2) | 0.98 | 30.2 (16.7–43.7) | 0.036 |
| Yes | 4.8 (2.7–7.0) | 14.7 (7.6–21.8) | ||
| Number of metastatic sites | ||||
| < 3 | 5.2 (4.6–5.8) | 0.684 | 22.1 (9.2–35.1) | 0.816 |
| ≥ 3 | 4.4 (1.1–7.7) | 17.4 (10.0–24.8) | ||
| Lines of treatment | ||||
| < 3 | 6.1 (3.4–8.7) | 0.875 | 17.4 (12.3–22.5) | 0.734 |
| ≥ 3 | 5.2 (4.0–6.4) | 24.7 (11.2–38.1) | ||
| Initial dose of apatinib | ||||
| 425 mg/day | 3.7 (2.6–4.9) | 0.100 | 14.7 (5.2–24.2) | 0.542 |
| 500 mg/day | 7.0 (3.5–10.5) | 22.0 (13.5–30.5) | ||
| Hypertension | ||||
| No | 4.4 (2.5–6.3) | 0.587 | 15.6 (1.8–29.5) | 0.563 |
| Yes | 5.4 (4.0–6.8) | 18.2 (8.2–28.3) | ||
| Hand-foot skin reaction | ||||
| No | 5.1 (3.7–6.4) | 0.951 | 14.7 (7.7–21.7) | 0.516 |
| Yes | 5.4 (3.2–7.5) | 22.0 (15.3–28.7) | ||
| Proteinuria | ||||
| No | 4.4 (2.6–6.1) | 0.271 | 14.7 (10.4–18.9) | 0.555 |
| Yes | 8.1 (5.2–11.0) | 22.1 (13.9–30.4) | ||
| Grade 3/4 adverse event | ||||
| No | 5.1 (1.7–8.4) | 0.361 | 17.4 (4.7–30.2) | 0.414 |
| Yes | 5.4 (3.3–7.5) | 14.7 (6.8–22.6) | ||
| Delayed administration | ||||
| No | 3.6 (1.4–5.8) | 0.008 | 15.8 (2.4–29.2) | 0.728 |
| Yes | 7.0 (3.3–10.6) | 18.2 (8.1–28.4) | ||
PFS, progression-free survival; OS, overall survival.